Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects

Publikation: Bidrag til tidsskriftReviewpeer review

DOI

  1. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jason Charles Ray
  • Mahima Kapoor
  • Richard J Stark
  • Shuu-Jiun Wang
  • Lars Bendtsen
  • Manjit Matharu
  • Elspeth Jane Hutton
Vis graf over relationer

Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.

OriginalsprogEngelsk
TidsskriftJournal of neurology, neurosurgery, and psychiatry
ISSN0022-3050
DOI
StatusE-pub ahead of print - 2021

Bibliografisk note

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 62004232